pyrazines has been researched along with thiostrepton in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gartel, AL; Pandit, B | 4 |
| Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Hussain, AR; Siddiqui, K; Uddin, S | 1 |
| Gartel, AL; Wang, M | 1 |
| Banerjee, A; Gartel, AL; Halasi, M; Kabirov, K; Landolfi, J; Lyubimov, AV; Wang, M | 1 |
7 other study(ies) available for pyrazines and thiostrepton
| Article | Year |
|---|---|
New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Humans; Male; Nitrophenols; Nucleosides; Peptides; Piperazines; Prostate; Pyrazines; Pyrimidines; Sulfonamides; Thiostrepton | 2010 |
Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; HCT116 Cells; Humans; Neoplasms; Pyrazines; Thiazoles; Thiostrepton | 2011 |
FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Leupeptins; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Thiostrepton | 2011 |
Proteasome inhibitors suppress expression of NPM and ARF proteins.
Topics: ADP-Ribosylation Factors; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression; HeLa Cells; Humans; Leupeptins; Nuclear Proteins; Nucleophosmin; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Thiostrepton | 2011 |
Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression; Humans; Immunohistochemistry; Ki-67 Antigen; Lymphoma, Large B-Cell, Diffuse; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Molecular Targeted Therapy; Primary Cell Culture; Proliferating Cell Nuclear Antigen; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Thiostrepton; Tumor Stem Cell Assay | 2012 |
Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Male; Mice; Mice, Nude; Nanocapsules; Proteasome Endopeptidase Complex; Pyrazines; Random Allocation; Thiostrepton; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Diethylnitrosamine; Disease Models, Animal; Liver; Liver Neoplasms; Mice; Phenobarbital; Pyrazines; Thiostrepton | 2012 |